Renal Newswire
- Mitsubishi Tanabe Pharma will receive and review grant funding
requests for the following areas of therapeutic interest:
• Uremic pruritus associated with hemodialysis
• Optimization of care for patients with renal disease
Click here to learn more about our educational grant request policy and information on how to submit a grant request - Click here to view abstracts from American Society of Nephrology Kidney Week 2012
- See our ads running in ASN Kidney News
Welcome
Members of the kidney community – people with chronic kidney disease, their families, caregivers, and healthcare professionals – visit this site for information on:
Treatment advances
The Research section of this site outlines the products in development at Mitsubishi Tanabe Pharma Corporation, the parent company of Mitsubishi Tanabe Pharma America (MTPA). Our goal: to innovate kidney care by offering new solutions to the challenges of preventing and treating kidney disease.
Kidney disease
On this website, you will find valuable information on kidney disease risk factors.
Our commitment to the kidney community
Please read the message from our president regarding our close relationship with the kidney community.
Thank you for visiting us. We are glad that you are here.
Watch the MTPA Story
Mitsubishi Tanabe Pharma:
America’s new pharmaceutical company over 300 years in the making
